Functional Connectivity Abnormalities of the Subgenual Anterior Cingulate Cortex: Implications for Transcranial Magnetic Stimulation in Depression
Xiao Chen,Bin Lu,Yu-Wei Wang,Xue-Ying Li,Zi-Han Wang,Hui-Xian Li,Yi-Fan Liao,Daniel M. Blumberger,Francisco Xavier Castellanos,Li-Ping Cao,Guan-Mao Chen,Jian-Shan Chen,Tao Chen,Tao-Lin Chen,Yan-Rong Chen,Yu-Qi Cheng,Zhao-Song Chu,Shi-Xian Cui,Xi-Long Cui,Zhao-Yu Deng,Qing-Lin Gao,Qi-Yong Gong,Wen-Bin Guo,Can-Can He,Zheng-Jia-Yi Hu,Qian Huang,Xin-Lei Ji,Feng-Nan Jia,Li Kuang,Bao-Juan Li,Feng Li,Tao Li,Xue Li,Tao Lian,Xiao-Yun Liu,Yan-Song Liu,Zhe-Ning Liu,Yi-Cheng Long,Jian-Ping Lu,Jiang Qiu,Xiao-Xiao Shan,Tian-Mei Si,Peng-Feng Sun,Chuan-Yue Wang,Han-Lin Wang,Hua-Ning Wang,Xiang Wang,Ying Wang,Chen-Nan Wu,Xiao-Ping Wu,Xin-Ran Wu,Yan-Kun Wu,Chun-Ming Xie,Guang-Rong Xie,Peng Xie,Xiu-Feng Xu,Zhen-Peng Xue,Hong Yang,Jian Yang,Hua Yu,Yong-Qiang Yu,Min-Lan Yuan,Yong-Gui Yuan,Yu-Feng Zang,Ai-Xia Zhang,Ke-Rang Zhang,Wei Zhang,Zi-Jing Zhang,Jing-Ping Zhao,Jia-Jia Zhu,Xi-Nian Zuo,the DIRECT Consortium,Chao-Gan Yan
DOI: https://doi.org/10.1101/2023.03.09.531726
2023-01-01
Abstract:Background The subgenual anterior cingulate cortex (sgACC) plays a central role in the pathophysiology of major depressive disorder (MDD), and its functional interactive profile with the left dorsal lateral prefrontal cortex (DLPFC) is associated with transcranial magnetic stimulation (TMS) treatment outcomes. Nevertheless, previous research on sgACC functional connectivity (FC) in MDD has yielded inconsistent results, partly due to small sample sizes and limited statistical power. Furthermore, calculating sgACC-FC to target TMS on an individual level is challenging because of the low signal-to-noise ratio and the poor replicability of individualized functional brain images.
Methods Leveraging a large multi-site cross-sectional sample (1660 MDD patients vs. 1341 healthy controls) from Phase II of the Depression Imaging REsearch ConsorTium (DIRECT), we systematically delineated case-control difference maps of sgACC-FC. Then, in a sample of 25 individuals with treatment-resistant depression who had received repetitive TMS (rTMS) treatment, we examined the relationship between case-control differences in FCs between sgACC and their specific TMS targets and treatment outcomes. Next, we tested whether the position of the group mean FC-based target (previously determined in healthy participants) differed in MDD patients. Finally, we developed a dual regression (DR) based approach to integrate group-level statistical maps with individual-level spontaneous brain activity to evaluate individualized TMS target localization in MDD. We tested this approach in a sample of 16 individuals who had received rTMS.
Results We found enhanced sgACC-DLPFC FC in MDD patients. The magnitude of case-control differences in FC between sgACC and TMS targets was related to clinical improvement. We found different peak sgACC anticorrelation locations in mean FC maps of MDD patients and HCs. More effective TMS targets were closer to individualized DR-based loci than to group-level targets.
Conclusion In summary, we reliably delineated MDD-related abnormalities of sgACC-FC profiles in a large independently ascertained sample and demonstrated the potential impact of such case-control differences on FC-guided localization of TMS targets. The proposed individualized approach for TMS targeting has the potential to improve TMS treatment outcome and warrants prospective clinical trials.
### Competing Interest Statement
DMB receives research support from the Canadian Institutes of Health Research (CIHR), National Institutes of Health-US (NIH), Brain Canada Foundation, and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he was the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He received in-kind equipment support from Magventure for investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. He has participated in an advisory board for Janssen. He has participated in an advisory board for Welcony Inc.